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Abstract 
 
The neuronal ceroid lipofuscinoses are a group of severe and progressive 
neurodegenerative disorders, generally with childhood onset. Despite the fact that 
these diseases remain fatal, significant breakthroughs have been made in our 
understanding of the genetics that underpin these conditions. This understanding has 
allowed the development of a broad range of models to study disease processes, and 
to develop new therapeutic approaches. Such models have contributed significantly to 
our knowledge of these conditions. In this review we will focus on the advantages of 
each individual model, describe some of the contributions the models have made to 
our understanding of the broader disease biology and highlight new techniques and 
approaches relevant to the study and potential treatment of the neuronal ceroid 
lipofuscinoses. 
 
Introduction 
 
The neuronal ceroid lipofuscinoses (NCLs), as with all neurodegenerative diseases, 
represent a highly complex biological problem. With all challenging biological 
questions, model organisms, which allow the researcher to attune the complexity of 
the model to the complexity of the task at hand, represent an invaluable tool. 
The NCLs are a group of lysosomal storage disorders of related clinical pathology. 
They are characterised by neurodegeneration, leading to a progressive decline in 
cognitive and motor function, blindness and epilepsy, eventually leading to premature 
death. NCLs have traditionally been categorised based upon their age of onset but as 
the underlying genetics of these diseases has become clearer, the NCLs are now sub-
divided based upon the causative genetic defect [1]. Individually these different forms 
of NCL are rare. Together however they represent the most common cause of 
childhood neurodegeneration, with an incidence, depending upon global variation, of 
between 1:12,500 and 1:100,000 [2]. Given that these conditions remain fatal with 
few therapeutic options available to slow disease progression or ease patient 
suffering, they represent a significant unmet clinical need. 
All basic biology and pre-clinical therapeutic development requires relevant model 
systems, from larger animal models for the development of therapies and therapeutic 
technologies to simple single cellular systems for the study of cell biology and 
systems-level experimentation. The NCL field has developed a range of such models, 
which have now been used extensively to study the biology of NCLs and to aid in 
therapeutic development. Animal models used to study NCLs include classical model 
systems, such as the mouse, fruit fly, nematode and zebrafish, and larger animal 
models, including dogs, sheep and cattle. The high degree of evolutionary 
conservation of some of these genes has even allowed the development of yeast 
models [3]. 
The model organisms available to study the NCLs have been reviewed in 
significant depth previously [3]. Consequently, in this review these contributions will 
only be summarised. Instead, the aim is to provide a more detailed account of the 
advantages of each of these model systems, to highlight new research findings, and to 
describe new techniques and approaches likely to be of benefit to NCL researchers in 
the future. The availability of such a range of systems provides a unique tool kit for 
studying NCLs, from mammalian models for disease pathology and therapeutic 
development to simpler systems allowing a more detailed understanding of basic 
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biology. The unique features of these individual models form the main focus of this 
review. 
 
Large animals 
 
Numerous naturally occurring large animal models of the different forms of NCL 
have been described since the first report in two English Setter dogs in 1953 [4]. The 
most important to date are the sheep and the dog, but the disease has also been 
reported and studied in other species such as cattle, horses, pigs, goats, cats, ferrets, 
birds and monkeys. The study of these models has largely contributed to a better 
understanding of the pathophysiology of the disease. Despite the more recent 
development of genetically modified mouse models, these large animal models are 
still valuable. The anatomy of their gyrencephalic brain is closer to human brain 
anatomy than the lissencephalic brain of rodents. Consequently, the phenotype of 
these affected animals more closely mimics the clinical signs of NCL observed in 
humans with their longer lifespan allowing a more thorough evaluation of potential 
therapeutic strategies. For these reasons, large animal models are an excellent 
complement to laboratory animals. The following section will describe NCL 
pathology in these models and illustrate their importance to our understanding of the 
pathophysiology and biochemisty of the NCLs. For brevity, the other large animal 
affected by NCL will be summarised and referenced in table S1. 
 
 
Modeling NCLs in large animals 
 
The disease was first described in a flock of South Hampshire sheep in New 
Zealand in 1976 by Jolly and colleagues [5]. The clinical signs start at 7 months of 
age and are usually early signs of blindness that is initially of cerebral origin but as 
the disease progresses retinal degeneration become more apparent. As the animal 
ages, other signs such as ataxia and decreased mentation become apparent and, in 
later stages, partial seizures occur before death by two years of age [6, 7]. The disease 
is caused by a mutation in CLN6 [8-10] and another mutation in the same gene causes 
similar pathology in Merino sheep [9, 11]. 
A similar phenotype affecting Borderdale sheep was reported in 2002 by Jolly et 
al. [12] and a colony was established. The causative mutation was found in CLN5 
[13], which is mainly responsible for the late infantile form of NCL in humans 
formerly known as the “Finnish variant” [14]. 
A form of NCL affecting newborn White Swedish Landrace Sheep was reported 
on a Swedish experimental farm [15]. The main clinical signs include tremors and 
weakness, an inability to suckle and marked cerebral atrophy [15]. A mutation in the 
cathepsin D gene was later identified [16, 17]. Interestingly, a mutation in this gene 
was subsequently identified in a newborn infant with severe microcephaly and was 
assigned CLN10 [18].  
Multiple forms of NCL have been described in numerous breeds of dogs. In most 
cases these have been sporadic descriptions of clinical cases and only a few colonies 
have been established and studied as animal models for NCL research. 
The English Setter was the first described animal model of NCL and most canine 
studies were performed in this breed. The clinical signs start at 14-18 months and are 
characterised by decrease mentation, ataxia and blindness. Convulsions occured a few 
months later and no animal survived to more than 26 months of age [19]. A mutation 
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in CLN8 was identified as the cause of the disease in this breed [20]. The research 
colony is no longer active, but frozen semen has been stored [21].  
At least three different forms of NCL have been reported in Dachshunds. The first 
one, in longhair Dachshunds, is caused by a mutation in the TPP1 gene (CLN2). 
Progressive neurological signs include mental retardation, ataxia, blindness and 
general myoclonus by 9 month of age [22]. A research colony has been established 
[23], which to the authors’ knowledge, is the only currently available canine colony. 
In people, mutation in CLN2 mainly results in a classic late infantile form, with 
mental retardation, epilepsy and vision deficits [14, 24]. 
NCL has also been reported in numerous other species including cows [25] 
monkeys [26], ferrets [27], cats [28, 29], pigs [30], goats [31] horses [32] and birds 
[33, 34]. Specific mutations are listed in table S1. 
Similar to humans with NCL, the main gross pathological findings in large animals 
consist of different degrees of cerebral and cerebellar atrophy [19, 35-37]. 
Histopathologically, there is neuronal loss and astrocytosis accompanied by the 
accumulation of autofluorescent storage material that is the hallmark of the NCLs. 
The South Hampshire sheep played a key role in the identification of subunit c of 
mitochondrial ATP synthase as a major component of the storage material in some 
forms of NCL [38, 39] and was also used to demonstrate that the degree of 
neurodegeneration is not correlated with lipopigment accumulation [40]. Due to their 
relatively complex cortex, sheep models of NCL have been used to study the selective 
and sequential degeneration of GABAergic interneurons in different regions of the 
brain [40]. A regional neurodegeneration in GABAergic neurons was also reported in 
the English Setter dog model [41]. Impaired neuronal synaptic function has also 
recently been reported in cell culture from sheep with CLN6 mutation [42]. 
Recent studies suggest that impaired metal ion homeostasis plays an important role 
in the pathophysiology of different neurodegenerative diseases [43] and a similar 
finding has been reported in Merino and South Hampshire sheep carrying CLN6 
mutations [44]. This could be secondary to the progressive loss of the metal 
transporter Zip7 observed in the affected sheep [45] and connected with the increases 
in levels of α-Synuclein, implicated in Parkinson’s disease, and the metal transporter 
ATP13A2, which is mutated in an inherited form of early-onset Parkinsonism [45, 
46]. Increased levels of superoxide dismutase were all seen in these sheep and likely 
reflect chronic oxidative stress. Taken together, findings from the sheep models point 
to chronic neural inflammation as important part of the disease process, as is thought 
likely for other neurodegenerative disorders. 
Large animal models have greatly contributed to the understanding of the 
pathophysiology of blindness, most particularly the retinal changes. Multiple 
functional, histopathological and ultrastructural studies have been performed in 
different large animal models and although most animal models show retinal changes, 
there is variability in the severity and distribution of the histopathological changes 
and their associated functional consequences. Dachshunds with CLN2 mutation [23, 
47], Polish Owczarek Nizinny dogs [48, 49], Miniature Schnauzer [50], Devon cattle 
(CLN5) [51] and  South Hampshire sheep (CLN6) [7, 52-54] show marked retinal 
atrophy and loss of the rod and cone layer with associated electroretinographic 
changes, in line with observations in humans with mutations in the same genes [55].  
In contrast, English Setters (CLN8) [54, 56, 57], American bulldogs (CLN10) [58] and 
Dalmatians [54, 59] show less severe retinal changes and the photoreceptor layer is 
not affected, which again mirrors the presentations in humans with these mutations 
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[55]. Despite its late onset form, Tibetan terriers (ATP13A2) [60] also show marked 
retinal and photoreceptor changes at a more advanced stage of the disease. 
  
Large animal models: A therapeutic focus 
 
Depending on the form of NCL, different therapeutic approaches have been 
considered, including various forms of enzyme replacement therapy (ERT) and gene 
therapy, and large animal models have proved invaluable for pilot studies. Initially, 
haematopoetic cell transplantation was attempted in the English Setter (CLN8) and 
South Hampshire sheep (CLN6) but with no effect on disease progression [61, 62]. 
This approach was unlikely to succeed considering the transmembrane nature of the 
deficient protein in these forms of NCL, although a recent abstract suggests that 
intercellular correction occurs in chimeric sheep created by merging blastomeres from 
normal and CLN6 affected embryos [63].  However, in forms of NCL resulting from 
deficiencies in lysosomal enzymes, such as CLN1, CLN2 and CLN10 diseases, direct 
supplementation can be considered. Dachshunds lacking the tripeptidyl peptidase-1 
enzyme (TPP1, or CLN2) represent an excellent model for this type of strategy. Early 
studies suggest that intrathecal or intracerebroventricular administration of 
recombinant human TPP1 can delay the clinical signs [64]. 
Viral vector mediated gene therapy is another more recent therapeutic approach 
that has shown promising results in ovine CLN5 neuronal cell cultures [65]. Initial 
studies in unaffected sheep confirmed extensive protein expression from the AAV9 
vector [66] and the first results from dogs (CLN2 Dachshunds) showed that viral 
transduction resulted in an increased enzymatic activity and delayed clinical 
progression [67]. Directed therapy to treat retinal degeneration in CLN2 Dachshunds 
by implanting genetically modified autologous bone marrow stem cells into the eye is 
now being developed, with some positive initial results [68]. 
Large animal models are potentially very useful to test drug therapies. Palliative 
treatment with the anti-inflammatory minocycline that is currently in human clinical 
trials was assessed in a sheep model of NCL (South Hampshire, CLN6) but showed 
no ability to inhibit microglial activation or astrocytosis [69]. However, for 
interventions to be assessed quantitatively for therapeutic efficacy, more accurately, 
longitudinal biomarkers for disease progression are necessary. To this end, recent 
studies have focused on characterising the behavioural changes in these animal 
models more accurately [70, 71]. 
 
Mice 
 
Historically, mouse models of neurodegenerative genetic disease have played a 
pivotal role in attempts to understand the neurobiology underpinning these complex 
disorders. They represent a logical progression from fly or zebrafish models as a more 
complex mammalian system with a greater genetic, anatomical and physiological 
similarity to human patients. They are easy to handle, have a high reproductive rate 
and are relatively cheap compared to other mammalian model systems. Such mouse 
models may arise through natural de novo mutation, induced random mutagenesis or 
by targeted molecular biology to disrupt a particular gene or genomic locus. The 
resolution of such disruptions can vary from deletion of multiple exons from a gene of 
interest to specific point mutations that accurately mimic the genetic defect in 
patients. There is no guarantee that the introduction of mutations to the mouse version 
of the gene will accurately recapitulate a phenotype similar to that observed in the 
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patient population. However, if they do then this represents an extremely powerful 
biological tool.  
Mouse models that faithfully recapitulate and mimic the human form of the disease 
have been used to confirm the role of candidate genes in the disorder. They can be 
used to study the underlying mechanism and progression of the disorder and this 
information can be used to design urgently required novel therapies or improve on 
existing ones. The identification of reliable biomarkers remains a high priority area in 
the neurodegenerative disease field and mouse models of disease provide an ideal 
resource in which to search. Finally, the model itself can be used to test potential 
novel therapies and small molecule drugs – do these have any disease modifying 
effects in the model, do they ameliorate the disease symptoms and pathology and do 
they rescue the model from premature death? Essentially, this is a fundamental 
species in which pre-clinical testing of therapies can take place before moving onto a 
larger model of the disease (if available) or moving directly into the clinic. The NCL 
field has greatly benefited from investment and a strategy to generate mouse models 
of the various forms of the disease.  
 
Modeling NCLs in mice 
 
There are currently 12 mouse models of NCL: Cln10 mouse [72], two Cln1 mice 
[73, 74], Cln2 mouse [75], Cln5 mouse [76], Cln6 mouse [77], Cln8 mouse [78], four 
Cln3 mice [79-82] and most recently a Cln7 mouse [83]. The reader is referred to a 
comprehensive review for details of the various features of the mouse models of 
NCLs with the exception of the recent Cln7 mouse [84]. In addition to these bona fide 
models of NCLs, there are other candidate mouse models that display features that 
resemble human NCL symptoms. These include null mutation in genes for ctsf [85], 
Ppt2 [73, 86] and the chloride ion channels Clcn-6 [87] and Clcn-7 [88]. However, it 
should be noted that none of these candidate models can be linked directly to 
established human forms of NCL.  
An obvious starting point of investigation in the NCL mice is the characterisation 
of temporal and spatial CNS pathology. All the models display the characteristic 
accumulation of fluorescent material and brain pathology and, where investigated, 
retinal involvement and premature mortality. However, there are also often both 
obvious and subtle differences between models of the different forms of the disease. 
Furthermore, there can be differences between the models of the same form of the 
disease. The four models of CLN3 disease provide a good example of this. The 
different mutations in the same gene lead to differences in the age of neurological 
symptom onset ranging from less than two months [80] to 16 months [82]. It is worth 
noting that this may be due to residual CLN3 activity due to variant mRNA 
transcripts [79] also reported in patient samples [89]. The Cln3 mice also differ from 
the other models in that although there is subtle activation of glial cells, there is not 
the prominent astrogliosis-associated proliferation or macrophage formation [90, 91]. 
 
Mouse models: A therapeutic focus 
 
The production and characterization of the models has undoubtedly furthered our 
understanding of the disease in its various forms and is an ongoing process. Perhaps 
the greatest value of the information gathered lies in the development of novel 
therapies. Any such endeavor requires knowledge of: (1) whether the mouse model is 
a reliable tool for therapeutic efficacy i.e. does the model faithfully recapitulate the 
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symptoms observed in patients (2) the target e.g. a particular cell type or receptor (3) 
when the therapeutic agent should be administered i.e. the therapeutic window of 
opportunity and (4) where it is required to be administered i.e. localised to one 
particular area or a broader anatomical distribution?. There is also the issue of 
selecting the most practical and suitable model for the desired experiment. For 
example, if a drug requires administration twice daily to a Cln3 mouse to measure 
delay of neurological onset or increase in survival, then the investigator may be 
advised to select the model that shows symptoms at 2 months rather than 16 months. 
It is clear that the vast majority of novel therapies have been tested in those models of 
NCLs that are associated with a defective or absent soluble enzyme. This includes 
ERT, stem cell and gene therapies.  
ERT has an established history in the lysosomal storage disorder (LSD) field and 
has revolutionised the treatment of patients e.g. Gaucher disease. The drawback is that 
intravenously administered recombinant enzyme may have a limited ability to cross 
the blood-brain barrier and so treating the CNS has proved difficult. However, high 
doses of intravenously administered recombinant Ppt1 enzyme have been shown to 
ameliorate pathology in the thalamic region of the brain in Cln1 mice leading to a 
subsequent later onset of motor function deterioration and extended survival. The 
effects of this approach are enhanced if therapy is initiated in the mice from birth [92] 
and highlights the importance of intervening within the optimal therapeutic window 
of opportunity. Similarly, the mouse model of Cln2 has also demonstrated 
amelioration of CNS pathology, reduced neurological symptoms and extended 
lifespan following intrathecal and intraventricular administration of recombinant 
Tpp1 enzyme [93, 94]. Encouragingly, this data in CLN2 mice has contributed to the 
initiation of a Biomarin Pharmaceuticals sponsored phase I/II clinical trial of 
recombinant Tpp1 enzyme (BMN-190) administered to patients with CLN2 disease 
via intracerebroventricular infusion (ClinicalTrials.gov identifier: NCT01907087).  
The recent ascendency of the gene therapy field has led to a number of successful 
clinical trials including paediatric neurological conditions such as X-linked 
adrenoleukodystrophy and metachromatic leukodystrophy [95, 96] and the mouse 
models of NCL have been used to evaluate similar gene therapy approaches as 
potential treatments. This has primarily been focused on the use of adeno-associated 
virus (AAV) gene delivery vectors that carry a therapeutic fully functional version of 
the defective gene and are administered directly into the brain. Promising results have 
been demonstrated in Cln1 [97-99], Cln2 [100-102] and Cln10 mice [103, 104] 
resulting in reduction of disease pathology and extension of lifespan. It is very likely 
that continued improvements in AAV vector design and production will lead to 
further enhancements in therapeutic efficacy and knowledge of the mouse model 
pathology is vital for this process. For example, targeting a particular cell type may 
dictate which particular serotype of AAV should be used and which promoter should 
be included to provide optimal expression of the delivered therapeutic gene. 
Knowledge of the areas of the brain that are affected is also vital to ascertain where 
the vector should be delivered, or indeed, if multiple sites of administration are 
required. Finally, an understanding of the timing of disease progression will influence 
at what stage the vector should be administered. The critical issue of intervening early 
and even pre-symptomatically has been demonstrated in a Cln2 mouse [100] and 
advantages of perinatal gene therapy has been recognised for some time [105, 106]. 
This is perhaps most critical in the context of acute paediatric neurodegenerative 
diseases where neurons must be rescued prior to irrevocable loss. The promising 
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results observed in the CLN2 mice led to a gene therapy clinical trial in patients 
[107]. 
Finally, stem cell therapies have also been tested in mouse models. Human neural 
stem cells have been administered to the brains of neonatal Cln1 mice that have been 
crossed with immunodeficient severe combined immunodeficiency (SCID) mice to 
avoid rejection [108]. Beneficial effects included a reduction in autofluorescent 
material and delay in motor function deterioration. These findings led to a phase I 
clinical trial in CLN1 and CLN2 patients that showed that transplanted cells did not 
trigger any adverse effects and supports further investigation [109]. 
Comparatively less progress has been made in developing treatments in the mouse 
models that mimic the defects in transmembrane protein forms of NCL. They do 
represent a more difficult target compared to the soluble enzymatic forms - they 
cannot be secreted and recaptured by neighbouring cells making cross-correction 
void. This effectively excludes ERT as a realistic approach. Gene therapy is still a 
viable therapeutic option but will probably require much higher levels of transduction. 
However, a recent study has shown that AAV-mediated gene delivery to the brains of 
neonatal Cln3 mice has therapeutic benefit leading to a reduction in storage material, 
gliosis and evidence of improved neuron counts [110]. Pharmacological therapies 
have also been tested in CLN3 mice including NMDA and AMPA receptor 
antagonists that lead to improved motor function [111, 112]. 
The contribution that the current repertoire of NCL mouse models available has 
had on furthering our understanding of this group of diseases is huge. This is evident 
from the continual investigation into new therapies, many of which have made their 
way to clinical trial. This is very encouraging and strongly supports continued 
investment of resources into the study and use of these models but also the generation 
of novel models.  
 
Zebrafish 
 
Zebrafish are small freshwater fish that have for many years been an important 
research tool. While previously used predominantly by developmental biologists, 
zebrafish are now established as a vertebrate disease model, and are increasingly 
being used to study neurodegenerative disease. The zebrafish genome can be easily 
manipulated and the availability of the latest reference assembly (GRCz10) on 
bioinformatics databases further supports its use. Orthologues of all NCL-causing 
genes exist in zebrafish and are highly conserved; in some cases more than one copy 
is present due to duplication of an ancestral locus during evolution [113].  
Zebrafish have many useful characteristics for disease modelling: they are 
vertebrates and therefore more similar in their development and physiology to 
mammals than other model organisms such as fruit flies; a single pair can produce 
several hundred rapidly-developing offspring per week, meaning that statistically 
significant sample sizes can be reached quickly and larval development is transparent, 
enabling high quality imaging techniques to be used to view the developing animal 
[114].  
Drug-target validation is a highly advantageous feature of zebrafish, enabling 
simultaneous toxicity and efficacy testing in a whole organism. Disease phenotypes 
manifest early in development and phenotypic endpoints may include behavioural 
testing or the monitoring of fluorescent reporters, for example [114]. Importantly, 
candidate compounds can be delivered by simple addition to the tank water. 
Illustrative of the potential of zebrafish for drug discovery is the identification of the 
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first bone morphogenetic protein inhibitor, a derivative of which successfully treats 
fibrodysplasia ossificans progressiva [115]. In addition zebrafish research led to the 
identification of a number of modifiers of gluconeogenesis [116] and the repurposing 
of leflunomide (previously a treatment for rheumatoid arthritis) to suppress melanoma 
[117].  
Large-scale mutagenesis screens have highlighted approximately 2000 genes 
involved in development [118, 119] and mutations in many genes relevant to 
neurological disease (including NCLs) continue to be found [120]; many of these 
alleles are currently available through the Wellcome Trust Sanger Institute, Hinxton 
UK.  
For quick, proof-of-principle enquiries into the function of zebrafish orthologues 
of human disease-causing genes, oligonucleotide-based knockdown studies are 
invaluable but suitable controls are essential [121]. Phenotypes are generally 
observable before 5 days post fertilization. Following initial analysis, knockout 
animals can also be generated for research im more stable systems.  
Both zinc-finger nucleases (ZFNs) [122] and transcription activator like 
endonucleases (TALENs) [123] have successfully knocked-out zebrafish genes. The 
current tool of choice is the Clustered Regularly Interspaced Short Palindromic 
Repeats (CRISPR)-associated system that uses the Cas9 nuclease to generate breaks 
or nicks in the chromosome [124]. This method also shows promise for the 
development of disease-specific knock-ins and the humanisation of zebrafish with 
healthy or mutant genes [125]. 
It should be noted that in some cases, phenotypes will either not develop or will 
manifest late in development. This may arise either due to redundancy in biological 
pathways or because physiological difference between zebrafish and man mean that 
pathological phenomena such as lipofuscin accumulation are unable to develop. For 
example, autofluorescent lipofuscin is undetectable in the zebrafish model of CLN2 
disease, although many other features representative of the disease do exist [126].  
 
Modeling NCLs in zebrafish 
 
To date, six zebrafish models of LSDs have been published but several are 
undergoing development; three of these are NCL models including CLN2, CLN10 and 
CLN11. These and other models for NCLs, are catalogued in table S2.  
CLN2 disease is caused by mutations in TPP1, encoding the lysosomal hydrolase 
tripetidyl peptidase (TPP1). The zebrafish model of CLN2 disease carries a missense 
mutation leading to a premature termination codon and complete loss of enzyme 
function. The lack of functional lysosomal Tpp1 leads to a number of phenotypes 
relevant to human disease including early neurodegeneration, reduced neurogenesis, 
epileptic seizures, motor abnormalities, visual defects and premature death [126].   
CLN10 disease is similarly caused by mutations in a lysosomal hydrolase, 
cathepsin D (CTSD). In humans CLN10 disease is very severe, causing congenital 
defects. The zebrafish model of CLN10 disease was generated by morpholino 
oligonucleotide knockdown and is characterized by small eyes due to the absence of 
retinal pigmented epithelial microvilli, disorganized musculature and premature death 
[127]. This model also exhibits lack of yolk resorption, a process reliant on autophagy 
and, by extension, lysosomal function. Mis-regulation of autophagy is thought to 
contribute to most neurodegenerative diseases. 
Mutations in GRNA, encoding granulin, cause CLN11 disease. Two groups have 
knocked-down grna, although neither group has validated the model with respect to 
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CLN11 disease. However, they observed motor neuron truncation and abnormal CNS 
development [128, 129]. Given that in humans, autosomal dominant GRNA mutations 
cause fronto-temporal lobar degeneration, a motor neuron disease variant, these 
phenotypes require further investigation. 
CLN3 disease is caused by mutations in CLN3, encoding a lysosomal 
transmembrane protein of unknown function. Data presented at a number of 
international conferences have described a zebrafish model of CLN3 disease 
generated by morpholino knockdown. This model exhibits small eyes, greatly 
disorganized neuronal axon pathfinding, astrocytosis, lysosomal storage of subunit c 
of mitochondrial ATP synthase, epileptic seizures, motor abnormalities and premature 
death (Wager at al., submitted).  
 
Zebrafish models: A therapeutic focus 
 
As highlighted above, zebrafish research has been used to directly inform therapy 
but as a relatively simple model, it is perhaps more ideally suited for the analysis of 
basic biological processes relevant to therapy. Although NCL research in zebrafish is 
a recently established field, zerbrafish have a much longer history of use for studying 
neurodegeneration as a whole, and comparative analysis of related disease models can 
be of significant value in informing therapy in a range of conditions. 
There are a range of established zebrafish models for neurodegeneration. Zebrafish 
models for Alzheimer’s disease include amyloid precursor protein morphants [130] 
and amyloid beta transgenic animals [131]. Aberrant phenotypes in zebrafish 
modelling Alzheimer’s disease include disordered movement. Transgenic models of 
tauopathy are also available [132, 133], which display both Tau accumulation and 
tangle formation, and Tau phosphorylation. There are also a wide range of models 
available to study Huntington’s and Parkinson’s diseases and amyotrophic lateral 
sclerosis (ALS). 
Huntington’s models include huntingtin transient overexpression models [134], 
transgenic animals [135] and morphants [136]. Studies in these models indicated 
protein aggregation, apoptosis, increased rhodopsin expression, developmental 
defects and embryonic lethality. Interventions such as inhibition of nitric oxide 
production and methylene blue treatment reduced aggregates in some of these studies. 
ALS models include Sod1 mutant overexpression [137] and transgenic models 
[138]. Other models include Tardbp mutant overexpression, transgenic or morphant 
animals [139, 140] and Fus transgenic animals [140]. These models display motor 
neuron and neuromuscular junction defects. Studies have indicated a rescue of these 
defects by upregulation of Vegf [137] or by methylene blue treatment [140]. 
Parkinson’s disease is probably the most broadly modelled neurodegenerative 
disease in zebrafish. Models include, Park2 [141], Pink1 [142-144], Park7 [145] and 
Lrrk2 [146] and cover morphant, transgenic and TILLING mutant models. 
Pharmacological models can also be obtained by MPTP exposure [147, 148]. 
Increased susceptibility to cellular stress and mitochondrial changes are common 
features of these models, and many recapitulate dopaminergic neuronal loss. 
A range of other neurodegenerative diseases have also been modelled, including 
frontotemporal dementia [149], spinal muscular atrophy [150, 151] and hereditary 
spastic paraplegia [152]. Such models recapitulate many aspects of these diseases, 
such as spinal motor neuron defects and associated behavioural changes. The 
successful modelling of multiple neurodegenerative diseases in zebrafish highlights 
its relevance as a model for NCLs. Further, the interventions that have been used in 
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these models to correct defects associated with neurodegeneration could inform future 
NCL research. 
 
Fruit Fly 
 
For more than a century Drosophila has been at the forefront of research into 
genetics, inheritance and development. A huge arsenal of genetic tools has been 
developed over that time and new tools continue to be developed that help to maintain 
the status of Drosophila as a key model for studying fundamental mechanisms. More 
recently, these powerful genetic tools combined with the short generation time (10 
days) and simple, cheap animal maintenance requirements have made Drosophila an 
attractive tool to model human disease. Approximately three quarters of human genes 
associated with disease are conserved in the Drosophila genome [153] and many 
inherited diseases have now been modelled in Drosophila. Although small in 
comparison to mammals, the Drosophila CNS shares many fundamental properties 
with the CNS of higher eukaryotes: it is isolated by a blood-brain barrier; neuron-glia 
interactions are critical for function and numerous neurotransmitters are used in 
different contexts, including glutamate, acetylcholine, dopamine, GABA and various 
peptidergic neurotransmitters. The adult Drosophila CNS also governs complex 
behaviours including mating routines, memory and learning, circadian rhythms, sleep, 
walking behaviour and flight navigation. Importantly, aspects of neuropathology are 
also similar, meaning that Drosophila has been used to investigate the cell biology of 
many of the common neurodegenerative diseases of humans, including both gain-of-
function disorders, such as tauopathies and triplet expansion diseases, and loss-of-
function diseases, such as inherited forms of Parkinson’s disease (reviewed in [154-
157]). 
 
 
Modeling NCLs in Drosophila 
 
In common with other invertebrates, Drosophila melanogaster has only a subset of 
the disease genes known to cause NCL in humans. These encode the lysosomal 
enzymes Ppt1 (CLN1) and Cathepsin D (CLN10), the endo-lysosomal membrane 
proteins, CLN3 and CLN7 (also known as MFSD8, encoded by CG8596 in 
Drosophila), and the synaptic vesicle protein cysteine string protein (CSP or CLN4). 
Additionally, Drosophila has genes encoding likely lysosomal chloride channels, 
including CLC-7 (CG8594), which is associated with NCL-like accumulation of 
lipofuscin and neurodegeneration [88]. Loss-of-function models have been generated 
for Ppt1 [158], cln3 [159], cathD [160] and cln7 (Megan O’Hare, Richard Tuxworth 
and Guy Tear, unpublished) to study cell biology of the NCLs. In contrast, 
Drosophila Csp has been studied extensively not as an NCL disease locus but rather 
for its functions at the synapse [161, 162], reviewed in [163]. Recent reviews have 
covered many of the findings from NCL studies using Drosophila and the reader is 
referred to these (see [84, 164]). Information and annotation of the Drosophila NCL 
genes, details of mutant alleles and transgenic constructs for each gene, fly lines and 
reagents available from the stock centres and all papers referring to NCL genes can be 
found on FlyBase (www.flybase.org). Instead, this perspective will focus on some of 
the techniques and tools developed more recently in Drosophila that could be used to 
help understand aspects of NCL cell biology in the future, including newly developed 
synaptic labelling tools and CRISPR-mediated genome editing. 
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The Drosophila research community was quick to adopt the CRISPR method of 
genome editing. CRISPR was adapted from a defence mechanism in the bacterium 
Streptococcus pyogenes and involves a nuclease, Cas9, being directed to a specific 
genomic location by a short (20 bp) guide RNA where it is generates double-stranded 
breaks (DSBs) in the chromosome. DSB repair occurs by one of two mechanisms: 
error prone non-homologous end joining (NHEJ), which results in insertions and 
deletions (indels), or homology-directed repair (HDR) by copying from a supplied 
template. HDR allows for insertions, base changes or other editing events to be 
included at the site. Simply change the guide RNA sequence and the mutations are 
directed elsewhere in the genome [165, 166]. 
More than 20 papers have been published in the last two years detailing strains, 
reagents and approaches to improve CRISPR mutagenesis in Drosophila (reviewed in 
[167]) and it is fast becoming a standard technique. Drosophila strains are available 
which express various forms of Cas9, including a mutated form that cannot generate 
DSBs so repair is biased towards HDR, and forms driven by various different 
promoters to improve efficiency. Numerous plasmids and other reagents have also 
been generated and made available via stock centres while protocols to test gRNA 
sites for efficiency of have been developed. CRISPR genome editing is also being 
combined with older genomic technologies such Recombination-Mediated Cassette 
Exchange (RCME) that enables rapid insertion of different cassettes into a single 
CRISPR-modified genomic strain, for instance to tag a gene with different fluorescent 
proteins or to generate conditional alleles [168]. 
The importance of CRISPR genome editing for research into the cell biology of the 
NCL disease genes in Drosophila is difficult to underestimate. By inserting sequences 
encoding fluorescent proteins or epitope tags into NCL gene loci the requirement for 
high affinity antibodies can be by-passed – a particular advantage for transmembrane 
proteins such as CLN3 and CLN7 that have proved poorly antigenic. Knock-in 
reporters will also circumvent a common issue encountered when vesicular proteins 
are fused to reporters and overexpressed: the protein sorting pathways can be 
swamped and the fusion protein found in multiple locations in the cell as a 
consequence. CRISPR could be used to knock-in molecular hooks for proteomics 
studies; genetically encoded reporters for cellular physiology studies; new markers for 
lysosomes can be generated; point mutations mirroring those found in human patients 
could be engineered into genes. While CRISPR technology will also provide these 
opportunities in other models and systems, the generation time of Drosophila will 
enable new in vivo reagents to be generated and combined with existing tools and 
reagents very rapidly. If the correct question is asked, CRISPR genome editing in 
Drosophila should speed up research into the cell biology of the NCLs dramatically. 
 
Drosophila models: A therapeutic focus 
 
Being a relatively simple model system, Drosophila are ideally suited to the 
analysis of the pathways that influence disease. Modifier screens are an established 
technique in the Drosophila field. Briefly, candidate screens or larger scale, random 
screens are performed to identify genes that modify a phenotype (usually when made 
heterozygous or when overexpressed). The phenotype needs to be easily scorable for 
higher throughput so degeneration present in the adult eye is often used as it can be 
seen with a dissection microscope. This approach has been used successfully to 
identify genes modifying phenotypes relating to Ppt1 [169] and cln3 [170]. These 
screens highlighted likely functions regulating endocytosis for Ppt1 [171], in stress 
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signalling for Cln3 [159] and in JNK signalling for both Ppt1 [171] and Cln3 [170]. 
More recently, new collections of RNAi lines have been generated for most genes in 
the Drosophila genome (www.flyrnai.org/TRiP-HOME.html). These lines 
complement previous collections and allow for very efficient, cell-type specific 
knock-down of gene expression via the UAS-GAL4 bi-partite expression system. A 
small candidate gene approach for the NCLs genes in Drosophila using some of these 
reagents has identified potential connections between Ppt1, cln3 and Cisd2 (also 
known as Wfs2), which is mutated in Wolfram Syndrome [172]. Wolfram patients 
develop childhood-onset optic atrophy and diabetes mellitus, usually followed by 
neurodegeneration. The cellular events that underpin the disease are perhaps better 
understood for Wolfram Syndrome than for the NCLs and endoplasmic reticulum 
stress is considered a major component [173]. Increases in ER stress markers have 
been reported previously in NCL studies [174, 175] and this type of genetic 
interaction study points to the common features in the cell biology underpinning 
different neurodegenerative syndromes. 
Synaptopathy – synaptic dysfunction associated with pathology - is an early 
hallmark of many neurodegenerative diseases and usually precedes overt neuronal 
loss. Synaptopathy also occurs in NCL models [176]. Given the early onset of 
neurodegeneration in the NCLs, it is likely that some of the CLN genes play a role in 
the development of the nervous system and/or the stability of synapses. The 
neuromuscular junction (NMJ) synapse of the Drosophila larva is an established 
model used to study synaptic development, composition, function and plasticity [177]. 
Motor neurons in Drosophila, in contrast to mammals, are glutamatergic and their 
synapses are structurally similar to central synapses of the mammalian CNS. 
However, unlike mammalian CNS synapses, they can be made readily accessible for 
electrical recordings and high-resolution microscopy by simple dissection (reviewed 
in [178-180]). The functions of several conserved components of synapses were 
elucidated in studies on the Drosophila NMJ, including those of CSP [161, 162]. 
Recently, super-resolution microscopy studies of the larval NMJ have provided 
exquisitely detailed information about the structure of synapses that will likely hold 
true for the mammalian CNS [181]. 
Changes in the electrical properties of larval motor neurons have been reported in 
Drosophila lacking Ppt1 function resulting in a locomotion deficit for the larva [182]. 
The phenotypes are rescued by re-expressing Ppt1 specifically in the nervous system, 
demonstrating that Ppt1 is required only pre-synaptically and consistent with a role in 
synaptic vesicle endocytosis. No changes were seen in the size of synapses in Ppt1 
mutant larvae but they are present in larvae lacking either cln3 or cln7 function along 
with changes in locomotion (Megan O’Hare, Richard Tuxworth and Guy Tear, King’s 
College London, unpublished observations). The size of the synapse is closely 
controlled by homeostatic mechanisms that match pre-synaptic innervation with the 
requirements of the post-synaptic muscle so the changes in synapse size indicate 
possible alterations to synaptic activity in these mutants which warrant further 
examination. Similarly, a careful assessment of the NMJs in cathD mutant larvae may 
also reveal synaptic functions for cathepsin D. 
By far the best understood of all the Drosophila NCL genes is Csp which was 
originally identified as a component of synapses via a monoclonal antibody screen 
[183]. There is only one Csp gene in Drosophila which corresponds to the CSP form 
in mammals. CSP is a palmitoylated protein containing a dnaJ chaperone-like domain 
and, given the function of PPT1 as a depalmitoylating enzyme, CSP is potentially a 
substrate of Ppt1. Csp mutants in Drosophila display severe defects in 
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neurotransmission [161, 162, 184] and it will be of interest, therefore, to determine 
whether combining Csp and Ppt1 mutations exacerbates either synaptic phenotype. 
The larval NMJ of Drosophila has been used extensively to study synaptic 
development in part because individual synapses and even sub-synaptic structures 
such as active zones can be visualised and quantified [178]. Many genes involved in 
human neurological disease have been shown to affect synapse number at the 
Drosophila NMJ but whether similar changes occur in the CNS – and therefore might 
also be occurring also in human neuropathology – is much more difficult to answer. 
Neurons in the insect CNS are tightly packed in a neuropil and individual synapses 
and active zones cannot be visualised so easily. Traditionally, serial scanning electron 
microscopy studies have been used to look at synapse number in neurodegenerative 
disease post-mortem tissue but these are laborious and can cover usually only small 
areas of the CNS. However, the development of genetic tools to label synapses in 
Drosophila may help to address these issues in the future. A recent light microscopy 
technique, Synaptic Tagging with Recombination (StaR) developed for Drosophila by 
the Zipursky lab [185] allows pre-synaptic active zones or post-synaptic receptor 
clusters to be labelled with epitope tags or fluorescent proteins and quantified in small 
subsets of neurons – small enough subsets that individual synapses can be visualised. 
A cell-type specific “flip-out” technique governs which neurons are labelled. This 
type of approach fits well with the Fly Light project at HHMI Janelia Farm Research 
Institute that has generated thousands of lines to control transgene expression in small 
subsets of neurons within the Drosophila CNS [186] (see www.janelia.org/team-
project/fly-light). Looking forward, it seems possible that we will be able to ask what 
happens to synapse number in Drosophila NCL and other neurodegeneration mutants 
in development and, potentially, as flies age and neurodegeneration progresses. 
 
 
 
 
Yeast 
 
Yeast are an invaluable tool for the study of eukaryotic cell biology. Yeast species 
have been utilized for decades to study basic cellular processes, such as cell division, 
protein and membrane trafficking and cell signaling. Yeast were also the first post-
genomic eukaryotic model [187], highlighting its regard as a key system in basic 
biology, and also many of the current advantages that yeast species afford. 
There are two commonly used yeast model systems, the budding yeast 
Saccharomyces cerevisiae and the fission yeast Schizosaccharomyces pombe. 
Although fission yeast has been used as a model system for a shorter period of time, 
both have similar tools and advantages. Their status as long-standing post-genomic 
models has allowed an understanding of the yeast genome in exceptional detail. This 
detailed genomic understanding has afforded an equally detailed analysis of the yeast 
transcriptome and proteome, allowing truly quantitative analysis of these ‘-omic 
profiles [188], the characterization of these profiles under different conditions and the 
influence of different regulatory processes [189]. This understanding has also been 
coupled with in silico techniques to predict and identify functional protein domains 
[190], predict protein interaction networks [191, 192], and to expand our 
understanding of metabolic processes [193]. Importantly, all this information is 
integrated into comprehensive genome databases [194, 195], providing an exceptional 
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level of information about a gene of interest before a single experiment need be 
performed. 
Another product of this advanced understanding is the presence of a wide range of 
functional genomic tools. Some of the most widely used and valuable of these tools 
are the yeast gene deletion collections [196, 197]. Importantly, these resources 
provide a platform for many technologies that are relevant to the study of disease. The 
combination of a genome wide-deletion collection, classical yeast genetic approaches 
and robotic technologies has facilitated the development of new functional genomic 
techniques. One of the most popular of these is the synthetic genetic array [198], 
which allows the generation of a genome-wide array of mutants, each also carrying a 
mutation in a query gene. Such approaches provide information about the functions 
with which a gene interacts, and can also highlight new potential therapeutic 
strategies. 
Yeast also have more direct applications in the development of therapies, and have 
been used in numerous and varied drug discovery projects [199]. One particular 
advantage of yeast is the ability to use the deletion libraries to identify drug targets by 
analyzing the effect of a drug on the fitness profile of the library [200], greatly 
streamlining phenotypic drug screening. 
 
Modeling NCLs in yeast 
 
Both budding and fission yeast have been used extensively to study the underlying 
biology of NCLs. CLN3 and CLN10 are conserved in budding yeast, whereas fission 
yeast has orthologues of CLN1, CLN3 and CLN10. In addition, budding yeast has a 
known orthologue of ATP13A2 (CLN12), one of the most recently identified NCL 
genes [201]. 
Much work in yeast has focused on the budding and fission yeast orthologues of 
CLN3 (BTN1 and btn1 respectively), which, like CLN3, are membrane proteins of 
unknown function. This work is reviewed in detail in [3], and will be summarized 
briefly here. Budding yeast BNT1 is known to localize to the vacuole and Golgi, and 
has an established role in vacuolar (the yeast lysosome) and cellular pH homeostasis, 
basic amino acid transport and storage and nitric oxide production [202-209]. Fission 
yeast btn1 displays the same localization pattern as BTN1, and regulates vacuolar pH 
and morphology, cell polarity, cell wall homeostasis, temperature sensitivity and 
osmotic homeostasis [210-212]. Fission yeast has also been used to highlight the 
different levels of function retained by different disease-causing mutations modeled in 
btn1 [213] and the metabolic changes, including increased glycolytic flux and TCA 
cycle activity, seen upon loss of btn1 [214]. It was also used to highlight a role for 
btn1 in membrane and protein trafficking [215]. Loss of btn1 has been shown to lead 
to the mis-sorting of the vacuolar protein carboxypeptidase Y, through processes both 
dependent on and independent of its sorting receptor Vps10. These observations were 
accompanied by changes in Golgi number, subcellular localization and morphology. 
A comparable role for BTN1 has also been reported, with BTN1 regulating Golgi 
morphology by modulating SNARE (SED5) phosphorylation by YCK3 [216]. 
Finally, BTN1 has been demonstrated to have a role in phospholipid homeostasis, in 
particular leading to a decrease in phosphatidylethanolamine levels [217]. 
The budding yeast orthologue of CLN10 (PEP4) is also well studied. CLN10/PEP4 
encodes cathepsin D, a vacuolar hydrolase. In work discussed in [3], PEP4 has been 
shown to mediate vacuolar protease maturation and vacuolar morphology [218]. 
PEP4 is also important in the maintenance of cells in quiescence, with its expression 
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increasing with cellular age [219]. Further, it has been shown that the catalytic 
activity of PEP4 protects against apoptosis, through the degradation of damaged 
macromolecules, while the pro-peptide protects against necrosis by promoting histone 
hypoacetylation, and the retention of pro-necrotic factors in the nucleus [220]. 
In more recent work, PEP4 has been demonstrated to be protective against acetic 
acid induced apoptosis [221]. During acetic acid induced stress, PEP4 translocates 
from the vacuolar lumen to the cytosol, where it is required for mitochondrial 
degradation, and the protection against oxidative damage that this affords. The 
catalytic activity of PEP4 is required for mitochondrial degradation, in a process that 
relies upon the mitochondrial AAC proteins, adenine nucleotide translocators found in 
the mitochondrial inner membrane [222]. 
The recent identification of ATP13A2 (CLN12) as the disease-causing gene in a 
rare case of juvenile NCL has highlighted the relevance of a number of yeast studies 
to NCL [201]. Many studies have investigated the cell biology of the yeast orthologue 
of CLN12 (YPK9), focusing particularly on its role in an early onset familial 
Parkinsonism (Kufor-Rakeb syndrome). CLN12 is a Golgi-resident P-type ATPase, a 
family of proteins that includes cation transporters. Consistent with this, the loss of 
YPK9 leads to sensitivity to cadmium, manganese, nickel and selenium, suggesting a 
role in cation transport [223]. 
In a genome-wide overexpression screen, YPK9 was identified as a suppressor of 
α-synuclein toxicity [224], the key component of Lewy bodies in Parkinson’s disease, 
which is also elevated in CLN3 disease models [225]. Increased expression of YPK9 
reduced the number of intracellular α-synuclein inclusions, but not total levels of 
protein. This effect was linked to a rescue of vesicular trafficking defects, allowing 
the exit of carboxypeptidase Y from the endoplasmic reticulum. Disease causing 
mutations linked to Kufor-Rakeb syndrome led to mis-localisation of YPK9 and 
prevented protection against toxicity. A mutation abolishing ATPase activity, by 
contrast, did not affect localization but also prevented protection. In this study, loss of 
YPK9 was again linked to manganese sensitivity. 
In a separate genome wide screen, this time looking at the interactions of YPK9 
itself, YPK9 was shown to interact with a number of genes known to be involved in 
protein trafficking and manganese homeostasis [226].  A particularly well represented 
group were those linked to vesicle-mediated transport. This included a number of 
VPS genes, the t-SNARE VAM3, the Rab YPT6, vacuolar transport chaperone 
complex members, and GLO3, an Arf GAP involved in ER-Golgi transport. 
 
Yeast models: A therapeutic focus 
 
Pathology in the NCLs have been linked to a wide array of cellular processes but 
altered lipid homeostasis, particularly changes in sphingolipids and ceramides, and 
lysosomal dysfunction are common themes for a broad range of NCL genes [227]. 
Both processes have been studied extensively in yeast, providing insights with 
relevance to disease and processes that could be relevant to therapy. 
Neurodegeneration can be thought of as a condition of impaired cellular lifespan. 
Cellular age in yeast is generally measured using two parameters: replicative lifespan 
(RLS), which is the number of divisions a cell goes through before death, and 
chronological lifespan (CLS), which is the amount of time a cell can survive in 
senescence [228]. In some of the earliest work to highlight genes involved in cellular 
ageing, budding yeast was used to identify LAG1 (Longevity-Assurance Gene 1), a 
gene that, when deleted, caused a 50% increase in replicative lifespan. LAG1 encodes 
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a component of ceramide synthase, which catalyses ceramide synthesis from 
dihydroceramide. Such an observation provides evidence that ceramide levels directly 
affect lifespan and interestingly,ceramide levels are perturbed in a number of NCLs 
[227]. CLN8 itself shares homology with LAG1, containing a TLC (TRAM–Lag1p–
CLN8) domain, suggesting a potential role in ceramide synthesis. Further, the human 
homologues of LAG1 can complement aspects of the loss of CLN9 [229]. 
The link between sphingolipids and cellular ageing extends beyond LAG1. IPT1, 
which catalyses the production of the terminal sphingolipid mannose-(inositol-P)2-
ceramide, increases CLS when deleted [230], and ISC1, an inositol 
phosphosphingolipid phospholipase C that produces ceramides, shortens CLS when 
deleted [231]. Lifespan in the latter deletion strain was greatly improved by deletion 
of SIT4 that  codes for a phosphatase positively regulated by ceramides [232], This 
ing suggests a link between the lifespan-altering effects of ceramides and downstream 
signaling processes. Interestingly, SIT4 is involved in a broad range of range of 
processes linked to NCL including; protein trafficking [233], glycogen metabolism 
[234], heat-shock functions, cytoskeletal organization and ribosome biogenesis [235], 
and vacuolar homeostasis [236]. 
The link between vacuolar homeostasis and cellular lifespan is not limited to 
ceramide-dependent processes. A study of how amino acid deprivation increases 
lifespan in yeast indicated that methionine withdrawal increases vacuolar acidification 
in a manner dependent upon autophagy. The authors then went on to demonstrate that 
increasing vacuolar acidification alone was sufficient to increase lifespan [237], 
providing evidence for a key role of vacuolar function in longevity. As well as low 
pH in the vacuole being protective against ageing, increasing pH has been shown to 
be a part of normal ageing in budding yeast. Increasing vacuolar pH has been 
demonstrated to lead to a decrease in vacuolar amino acid storage and was also 
coupled with an increase in mitochondrial dysfunction [238]. This link between 
vacuolar pH and mitochondrial dysfunction provides a key link between vacuolar 
changes, as observed in models for NCL, and defects known to contribute cell death 
with cellular increasing age [239].  
Yeast represent the simplest established model for eukaryotic cell biology, 
allowing the study of cellular processes at a depth not afforded by other systems. 
Further, the conservation of NCL genes in such a simple system suggests that they 
regulate fundamental cellular functions, and provides the opportunity to utilise the 
advantages of the yeast model. This approach has provided disease-relevant insights 
into the roles of CLN3, CLN10 and the newly identified CLN12. In addition, the level 
of information available regarding metabolic, biosynthetic and signaling pathways in 
yeast species can provide valuable information about processes involved in disease. In 
this review, such information regarding sphingolipid biosynthesis and vacuolar 
function has also been explored. 
 
Emerging models for NCLs 
 
There are relatively few models available for the study of adult onset NCLs. 
Beyond the cathepsin F (CLN13) knock-out mouse model for type B Kufs disease 
[240], and the DNAJC5 (CLN4) knock-out mouse, which provides a model for 
autosomal-dominant adult-onset NCL [241], there are few options for the study of 
these conditions. 
The nematode worm Caenorhabditis elegans provides a very simple multicellular 
eukaryotic model system with a highly stereotyped and defined development and 
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body plan [242]. C. elegans has orthologues of CLN3 and CLN10, however little work 
has been done to study these genes in the nematode (reviewed in [243]). C. elegans 
however has recently emerged as a potential model for autosomal-dominant adult-
onset NCL [244]. Nematodes lacking the orthologue of CLN4 (dnj-14), which 
encodes the molecular chaperone cysteine string protein α, exhibit reduced lifespan, 
locomotor defects and impaired neurotransmitter release. Underlying this phenotype, 
the worms exhibited an age-dependent decline in neuronal cell bodies, reduced 
neurite numbers and contorted neuronal processes, particularly in the head of the 
animal. Among the neurons lost, sensory neurons were particularly affected, leading 
to chemosensing defects. 
The lifespan defect in these worms was exploited to allow screening for potential 
therapeutic compounds. Resveratrol was the only compound to rescue this defect, in 
addition to giving a partial rescue of the neurodegeneration and chemotaxis 
phenotypes. Resveratrol has been described in the past as being beneficial for lifespan 
and, although the mechanism-of-action is unclear, it is known to activate the Sirtuin 
class of histone deacetylases and may act as a phosphodiesterase (PDE) inhibitor 
[245]. Consistent with a role as a PDE inhibitor, the rescue elicited by Resveratrol 
was mimicked by a known PDE antagonist Rolipram and consistent with this being 
the main therapeutic mechanism of Resveratrol in this case, the deletion of Sirtuin sir-
2.1 did not affect this rescue. These observations provide key information about the 
biology of CLN4 deficiency, as well as a new therapeutic mechanism. 
The social amoeba Dictyostelium discoideum is another very well-established 
eukaryotic model organism. Dictyostelium has been successfully used in a number of 
studies to examine the role of genes associated with neurodegenerative disorders 
[246-248], however it has only recently been used in the study of NCLs. In a recent 
study, however, the role of the Dictyostelium orthologue of CLN3 (Cln3) was 
explored [249]. Cln3 was shown to localise to the vacuolar and endocytic 
compartments of Dictyostelium, consistent with observations in other model systems. 
Cells lacking Cln3 exhibited altered trafficking and processing of autocrine 
proliferation repressor (AprA), leading to increased proliferation, suggesting changes 
in protein trafficking. Dictyostelium also has a well characterised life-cycle, involving  
the formation of coordinated multicellular aggregates (slugs), which was altered upon 
loss of Cln3. These cells displayed a more rapid development through their lifecycle 
and faster migrating slugs. All these pleiotropic effects were rescued by expression of 
Cln3, or human CLN3, indicating that these proteins are functional orthologues. 
In a later study, Dictyostelium was also used to analyse the role of CLN2 (TPP1) 
[250]. The Dictyostelium orthologue DdTpp1 was demonstrated to contribute to the 
cleavage of TPP1 substrate, suggesting the same role for ddTpp1 as TPP1. Both 
ddTpp1 and TPP1 were also demonstrated to localise to the lysosome of 
Dictyostelium. Like cells lacking Cln3, cells lacking ddTpp1 exhibited a more rapid 
multicellular development, possibly suggesting overlapping roles. Cells lacking 
ddTpp1 displayed further developmental changes, exhibiting defects in spore 
formation. These cells also exhibited clear defects in autophagy and lysosomal 
function, with autophagic stimulation leading to a reduction in cell size and viability 
and lysosomal perturbation leading to impaired development. Finally, this later 
phenotype could be supressed by the loss of an oxysterol-binding protein-like protein 
stpA, providing insights into the mechanism of this defect and a potential mechanism 
of supressing defects associated with the loss of TPP1. 
This work in both C. elegans and Dictyostelium provides new information about 
the roles of different NCL genes. Importantly this work also opens up the repertoire of 
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tools available to NCL research, providing valuable new models for the study of these 
diseases.  
 
Concluding Remarks 
 
Model organisms have provided a wealth of information about the processes that 
underlie the pathological changes observed in NCL. In addition, such models provide 
a means for the identification and development of much needed novel therapies. The 
work summarised in this review also highlights the advantages of these models, and 
the value of using a broad range of experimental systems in tackling complex 
biological problems such as neurodegenerative disease. Finally, by looking to broader 
related basic research in these models, we are able to gain an insight into the cellular 
processes which may influence disease. 
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Highlights 
 We discuss the developments made in model systems for the neuronal 
ceroid lipofuscinosis (NCL). 
 We discuss the advantages of each model and new tools available in these 
systems to aid NCL research. 
 We review the progress made in these models form the perspective of 
both basic biology and therapeutic development. 
